title: Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.
abstract: Secretion of growth hormone (GH) is excessive in acromegaly, but also in a number of other pathological states such as anorexia nervosa, insulin-dependent diabetes mellitus (IDDM), liver cirrhosis, depression, renal failure and GH-insensitivity syndrome. Abnormalities in the neuroendocrine control of GH secretion and/or a state of insensitivity to GH contribute to hypersecretion of GH in these states, with the possible exception of acromegaly, which appears to be a primary pituitary disease. GH hypersecretion may also occur in neonates or adolescents with tall stature, thus reflecting particular physiological or paraphysiological conditions. In the cohort of brain neurotransmitters, catecholamines and acetylcholine reportedly play a major role in the control of neurosecretory GH-releasing hormone (GHRH) and somatostatin (SS)-producing neurons, and hence GH secretion. Activation of alpha 2-adrenoceptors or of muscarinic cholinergic receptors in the hypothalamus stimulates GH release, probably through stimulation of GHRH and inhibition of SS release, respectively. Activation of dopamine receptors likewise stimulates GH release, while activation of beta-receptors inhibits GH release through stimulation of hypothalamic SS function. This review discusses the involvement of brain catecholamines and acetylcholine in GH hypersecretory states, including anorexia nervosa, acromegaly, IDDM, liver cirrhosis, depression, renal failure and GH insensitivity syndrome, with a view to providing a fuller understanding of their pathophysiology and, whenever possible, diagnostic and therapeutic implications.
authors.affiliation: Department of Pharmacology, University of Milan, Italy.
authors.forename: E E
authors.initials: EE
authors.lastname: Müller
authors.forename: M
authors.initials: M
authors.lastname: Rolla
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
authors.forename: D
authors.initials: D
authors.lastname: Belliti
authors.forename: E
authors.initials: E
authors.lastname: Arvat
authors.forename: A
authors.initials: A
authors.lastname: Andreoni
authors.forename: A
authors.initials: A
authors.lastname: Torsello
authors.forename: V
authors.initials: V
authors.lastname: Locatelli
authors.forename: F
authors.initials: F
authors.lastname: Camanni
mesh_terms: D000109:Acetylcholine / Q000502:physiology*; D000818:Animals; D000856:Anorexia Nervosa / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D002395:Catecholamines / Q000502:physiology*; D003866:Depressive Disorder / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D005260:Female; D013006:Growth Hormone / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism; D008297:Male; D010900:Pituitary Diseases / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy
chemical_list: D002395:Catecholamines; D013006:Growth Hormone; D000109:Acetylcholine